The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Uwe PlatzbeckerDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, How can we improve on current risk stratification in MDS?
How can we improve on current risk stratification in MDS?
In daily practice, the International Prognostic Scoring System (IPSS) and the revised IPSS are used for assessing prognosis and stratification of patients with MDS at diagnosis. However, in recent years, a lot of data have shown the impact of mutations in patients with MDS. Most of these mutations confer a poor prognosis when added to these risk stratification systems. Platzbecker underlines the importance of integrating these mutations into a holistic prognostication system, which should also include fatigue and patient-reported outcomes.